Kidney outcomes with SGLT2 inhibitor vs. DPP4 inhibitor use in older adults with diabetes.
Yuta SuzukiHidehiro KanekoAkira OkadaJin KomuroToshiyuki KoKatsuhito FujiuNorifumi TakedaHiroyuki MoritaAkira NishiyamaMasaki IedaKoichi NodeHideo YasunagaMasaomi NangakuIssei KomuroPublished in: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2024)
Our analysis, utilizing a nationwide epidemiological dataset, demonstrated that the decline in eGFR was slower in individuals aged ≥ 60 years with diabetes who were prescribed SGLT2 inhibitors compared to those prescribed DPP4 inhibitors, suggesting a potential advantage of SGLT2 inhibitors for kidney outcomes even in older individuals with diabetes.